What do systematic reviews say?

Mepolizumab 300 mg vs placebo

Mepolizumab 300 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (moderate certainty).

• Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  Rate ratio 0.86 [0.7, 1.06]
  1 study · 451 participants
  Moderate

Mepolizumab 300 mg vs placebo

Mepolizumab 300 mg probably leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (moderate certainty).

• Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  Hazard ratio 0.77 [0.6, 0.99]
  1 study · 451 participants
  Moderate

Mepolizumab 300 mg vs placebo

Mepolizumab 300 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).

• Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  Rate ratio 0.83 [0.51, 1.35]
  1 study · 451 participants
  Moderate

Mepolizumab 300 mg vs placebo

Mepolizumab 300 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  Odds ratio 0.84 [0.56, 1.27]
  1 study · 451 participants
  Moderate

Mepolizumab 300 mg vs placebo

• Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 451 participants
  Moderate